Patents by Inventor John M. Reno

John M. Reno has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOLABELED ANNEXINS
    Publication number: 20110269943
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: June 28, 2010
    Publication date: November 3, 2011
    Applicants: University of Washington, Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • Radiolabeled annexins
    Patent number: 7744853
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: June 29, 2010
    Assignee: Poniard Pharmaceuticals, Inc.
    Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
  • METHODS OF USE OF ANTIBODIES WITH REDUCED IMMUNOGENICITY OR TOXICITY
    Publication number: 20090094715
    Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.
    Type: Application
    Filed: March 19, 2008
    Publication date: April 9, 2009
    Inventors: Scott S. Graves, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Stephen M.J. Searle, Andrew H. Henry, Jan T. Pedersen, Anthony R. Rees
  • Streptavidin expressed gene fusions and methods of use thereof
    Patent number: 7144991
    Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
    Type: Grant
    Filed: December 7, 2001
    Date of Patent: December 5, 2006
    Assignee: Aletheon Pharmaceuticals, Inc.
    Inventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno
  • Radiolabeled annexins
    Patent number: 7115248
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: October 3, 2006
    Assignee: NeoRx Corporation
    Inventors: Sudhakar Kasina, John M Reno, Louis J Theodore
  • Pretargeting methods and compounds
    Patent number: 7078013
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: July 18, 2006
    Assignee: Aletheon Pharmaceuticals, Inc.
    Inventors: Donald B Axworthy, Louis J Theodore, Linda M Gustavson, John M Reno
  • Pretargeting methods and compounds
    Publication number: 20040241172
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Application
    Filed: February 10, 2004
    Publication date: December 2, 2004
    Applicant: NeoRx Corporation
    Inventors: Donald B. Axworthy, Louis J. Theodore, Linda M. Gustavson, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Alan R. Fritzberg
  • Therapeutic inhibitor of vascular smooth muscle cells
    Patent number: 6720350
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: April 13, 2004
    Assignee: SciMed Life Systems, Inc.
    Inventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
  • Pretargeting methods and compounds
    Patent number: 6709652
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as related compounds, are described. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are discussed.
    Type: Grant
    Filed: August 1, 2001
    Date of Patent: March 23, 2004
    Assignee: NeoRx Corporation
    Inventors: John M. Reno, Louis J. Theodore, Linda M. Gustavson
  • TGF-&agr; polypeptides, functional fragments and methods of use therefor
    Patent number: 6677307
    Abstract: Disclosed are TGF-60 mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: January 13, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell, John M. Reno
  • Therapeutic inhibitor of vascular smooth muscle cells
    Patent number: 6663881
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: December 16, 2003
    Assignee: NeoRx Corporation
    Inventors: Lawrence L. Kunz, John M. Reno
  • Radiolabeled annexins
    Publication number: 20030220233
    Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.
    Type: Application
    Filed: June 6, 2003
    Publication date: November 27, 2003
    Applicant: NeoRx Corporation
    Inventors: Sudhakar Kasina, John M. Reno, Louis J. Theodore
  • Therapeutic inhibitor of vascular smooth muscle cells
    Publication number: 20030203958
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Application
    Filed: December 27, 2002
    Publication date: October 30, 2003
    Applicant: NeoRx Corporation
    Inventors: Lawrence L. Kunz, Richard A. Klein, John M. Reno
  • Streptavidin expressed gene fusions and methods of use thereof
    Publication number: 20030143233
    Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, in the absence and presence of a radiation-sensitizing agent, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
    Type: Application
    Filed: September 16, 2002
    Publication date: July 31, 2003
    Applicant: NeoRx Corporation
    Inventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno, Erica A. Dearstyne
  • Pretargeting methods and compounds
    Publication number: 20030129191
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin, as well as related compounds, are described. Clearing agents and clearance mechanisms are also discussed.
    Type: Application
    Filed: April 17, 2002
    Publication date: July 10, 2003
    Applicant: NeoRx Corporation
    Inventors: Louis J. Theodore, Donald B. Axworthy, John M. Reno
  • Method of reducing immunogenicity of toxicity of an antibody of IgG class
    Publication number: 20030119078
    Abstract: Humanized antibodies which bind the NR-LU-13 antigen, conjugates containing such antibodies, and their use in pretargeting methods and conventional antibody therapy and immunodiagnosis are provided.
    Type: Application
    Filed: January 24, 2002
    Publication date: June 26, 2003
    Applicant: NeoRx Corporation
    Inventors: Scott S. Graves, John M. Reno, Robert W. Mallett, Mark D. Hylarides, Stephen M.J. Searle, Andrew H. Henry, Jan T. Pedersen, Anthony R. Rees
  • Streptavidin expressed gene fusions and methods of use thereof
    Publication number: 20030103948
    Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, in the absence and presence of a radiation-sensitizing agent, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
    Type: Application
    Filed: May 17, 2002
    Publication date: June 5, 2003
    Applicant: NeoRx Corporation
    Inventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno, Erica A. Dearstyne
  • Three-step pretargeting methods and compounds
    Publication number: 20030099640
    Abstract: Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, three-step pretargeting methods are described.
    Type: Application
    Filed: February 12, 2002
    Publication date: May 29, 2003
    Applicant: NeoRx Corporation
    Inventors: Louis J. Theodore, John M. Reno, Linda M. Gustavson
  • Therapeutic inhibitor of vascular smooth muscle cells
    Patent number: 6569441
    Abstract: Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: May 27, 2003
    Assignee: NeoRx Corporation
    Inventors: Lawrence L. Kunz, John M. Reno
  • Streptavidin expressed gene fusions and methods of use thereof
    Publication number: 20030095977
    Abstract: The present invention provides vectors for expressing genomic streptavidin fusion cassettes. In the various embodiments, fusion proteins produced from these vectors are provided. In particular embodiments, fusion proteins comprising a single chain antibody and genomic streptavidin are provided as are vectors encoding the same. Also provided, are methods of using the fusion proteins of the present invention, and in particular, the use of scFvSA fusion proteins as diagnostic markers or as a cell specific targeting agents.
    Type: Application
    Filed: December 7, 2001
    Publication date: May 22, 2003
    Applicant: Neorx Corporation
    Inventors: Stephen Charles Goshorn, Scott Stoll Graves, Joanne Elaine Schultz, Yukang Lin, James Allen Sanderson, John M. Reno